SIGA suspends work on $2.8 billion US smallpox drug contract after Chimerix objects
This article was originally published in Scrip
Executive Summary
Just two days after winning the first US contract to develop a smallpox antiviral drug supported through Project BioShield, SIGA Technologies revealed on 15 May that it was forced to suspend further work until a protest from rival Chimerix is resolved, which could take up to about three months.